Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
No Placebo
Drugs
Locations
Clinical Specialty
1561-1580 of 2,251 trials

Atrial Fibrillation: IV Flecainide with Ranolazine

We are comparing the effectiveness of a combination of IV flecainide and oral ranolazine against IV flecainide alone for patients with recent onset atrial fibrillation. This study aims to find out which treatment better restores normal heart rhythm.

Atrial Fibrillation (AF)Confirmation phase (III)≤5 visitsNo PlaceboStandard MedicinesCardiology

Irritable Bowel Syndrome: GSL-01-001 Treatment

We are testing a new oral medication for people with Irritable Bowel Syndrome to see if it helps control symptoms like pain and bloating. The study also aims to evaluate its safety and impact on quality of life.

Irritable Bowel Syndrome (IBS)6-12 monthsEfficacy phase (II)≤5 visitsNo PlaceboInvestigational MedicinesGastroenterology

Chronic Lymphocytic Leukemia: Venetoclax with Ibrutinib and Rituximab

We are studying a combination of venetoclax, rituximab, and ibrutinib for treatment-naïve patients with chronic lymphocytic leukemia. The aim is to see if this approach can lead to undetectable minimal residual disease.

Chronic Lymphocytic Leukaemia>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesOncology

Leukemia: Venetoclax with Stem Cell Transplant

We are evaluating the safety and effectiveness of Venetoclax combined with standard treatment for patients with high-risk MDS, CMML, or sAML undergoing stem cell transplantation. This study aims to improve outcomes and reduce complications during treatment.

Leukemia>2 yearsSafety phase (I)Efficacy phase (II)≤5 visitsNo PlaceboStandard MedicinesHematologyOncology

Ovarian Cancer: HIPEC Treatment Study

We are studying the effects of hyperthermic intraperitoneal chemotherapy (HIPEC) combined with standard care for ovarian cancer patients. This trial aims to see if HIPEC improves survival and quality of life compared to standard treatments alone.

Ovarian and Fallopian Tube CancerConfirmation phase (III)No PlaceboStandard MedicinesOncology

NPM1-Mutated Acute Myeloid Leukemia: Eltanexor Study

We are evaluating a new drug called eltanexor for patients with relapsed or refractory NPM1-mutated acute myeloid leukemia. The study aims to see if it is safe and effective in treating this condition.

Acute Myeloid LeukemiaEfficacy phase (II)16-20 visitsNo PlaceboInvestigational MedicinesPartially RemoteHematologyOncology

Antibiotic Treatment for Critically Ill Patients

We are studying whether a short course of high-dose antibiotics is as effective as standard treatment for critically ill patients with pneumonia, intra-abdominal infections, or bloodstream infections. This research may help reduce antibiotic use while maintaining patient safety.

Pneumonia and Bacterial Infections>2 yearsConfirmation phase (III)6-10 visitsNo PlaceboStandard MedicinesPartially RemoteInfectious DiseasesInternal Medicine

Juvenile Idiopathic Arthritis: Early Drug Withdrawal Study

We are exploring whether stopping medication early is safe and effective for children with juvenile idiopathic arthritis in remission. This study also aims to identify new biomarkers that may help predict flare-ups after treatment withdrawal.

Juvenile Idiopathic Arthritis3-6 monthsMonitoring phase (IV)6-10 visitsNo PlaceboStandard MedicinesPediatricsRheumatology

Inflammatory Bowel Disease: Vedolizumab Dose Reduction Study

We are studying whether patients with inflammatory bowel disease can safely lower their dose of vedolizumab. This trial will help us understand the effects on health, costs, and quality of life.

Inflammatory Bowel Disease1-2 yearsMonitoring phase (IV)≤5 visitsNo PlaceboStandard MedicinesPartially RemoteGastroenterologyInternal Medicine

Psoriasis: [18F]Fluoride PET-CT Imaging Study

We are investigating if [18F]Fluoride PET-CT scans can detect early bone changes in psoriasis patients at risk for psoriatic arthritis. This study aims to see if this imaging method is effective for early detection.

Psoriasis>2 yearsEfficacy phase (II)≤5 visitsNo PlaceboStandard MedicinesCost ReimbursementDermatologyRheumatology

Avacopan for Children with Active ANCA-associated Vasculitis

We are studying how well Avacopan works when combined with other treatments in children aged 6 to under 18 with active ANCA-associated vasculitis. The trial will also look at safety and how children respond to the medication.

ANCA-associated Vasculitis1-2 yearsConfirmation phase (III)11-15 visitsNo PlaceboInvestigational MedicinesCost ReimbursementInternal MedicineRheumatology

Osteosarcoma: Mifamurtide with Chemotherapy

We are studying whether adding mifamurtide to standard chemotherapy helps improve outcomes for patients with high-risk osteosarcoma. This trial is for individuals aged 2 to 50 who are newly diagnosed with this aggressive cancer.

High-Risk Osteosarcoma6-12 monthsEfficacy phase (II)No PlaceboStandard MedicinesOncology

Gastroenteropancreatic Neuroendocrine Tumors: New Liver Treatment

We are studying a new way to deliver radiolabeled treatments directly to the liver for patients with GEP-NET and dominant liver metastases. This trial aims to see if this method improves treatment effectiveness and safety.

Gastroenteropancreatic Neuroendocrine Tumors>2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesCost ReimbursementGastroenterologyInternal MedicineOncology

Prostate Cancer: Enzalutamide Study

We are investigating how Enzalutamide affects molecular changes in men with localized prostate cancer before and after surgery. This study may help us understand its impact on cell growth and gene activity.

Prostate Cancer>2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesOncologyUrology

Relapsed or Refractory Tumors: AcSé-ESMART Trial

We are studying new treatment options for children and adolescents with hard-to-treat tumors. The goal is to see if these treatments are safe and effective based on the specific characteristics of their tumors.

Pediatric Cancer>2 yearsSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesOncologyPediatrics

Kidney Transplant: Optimal Dose of Grafalon®

We are studying the best dose of Grafalon® for kidney transplant patients with low immunological risk. This trial aims to prevent complications and evaluate the medication's safety and effects on kidney function and infections.

Kidney TransplantKidney Insufficiency>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesInternal MedicineNephrology

Post-Surgery Pain Management: Ropivacaine Concentration Study

We are investigating whether different concentrations of ropivacaine can help reduce pain after volar plate surgery. This study aims to see if higher doses lead to less rebound pain and better overall pain control.

Radius Fracture>2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesPartially RemoteOrthopedics and TraumatologyOtolaryngologyPsychiatry

Kidney Health After Liver Transplant: Human Albumin Study

We are investigating whether higher doses of human albumin can help reduce kidney problems after liver transplantation. This study looks at various recovery aspects, including hospital stay and potential complications.

Liver Transplantation≤3 monthsMonitoring phase (IV)No PlaceboStandard MedicinesHepatologyNephrology

Lung Cancer: Pembrolizumab and Lenvatinib Combination Therapy

We are studying a new combination treatment for patients with operable Non-Small-Cell Lung Cancer to see if it improves response rates before surgery. We also aim to identify markers that may predict how well patients respond to this therapy.

Non-Small-Cell Lung Cancer1-2 yearsEfficacy phase (II)Post-Trial Drug AccessNo PlaceboStandard MedicinesOncologyPulmonology

Ovarian Cancer: Rinatabart Sesutecan (Rina-S) Study

We are comparing a new treatment, Rina-S, to standard therapies for patients with platinum-resistant ovarian cancer. The goal is to see if Rina-S can help improve survival without disease progression.

Platinum-resistant Ovarian Cancer>2 yearsConfirmation phase (III)No PlaceboInvestigational MedicinesOncology